Eric Lamarre MD

Dr. Eric Lamarre MD


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 July 2019 in The Laryngoscope
Verified
Journal Article
Closed access
WTWilliam S. Tierney
William S. Tierney
JSJanki Shah
Janki Shah
KCKate Clancy
Kate Clancy
MLMaxwell Y. Lee
Maxwell Y. Lee
PCPeter J. Ciolek
Peter J. Ciolek
EMEric Lamarre MD
Eric Lamarre MD

20 February 2023 in Head & Neck
Verified
Journal Article
Open access
SWShannon Wu
Shannon Wu
HHHanna Hong
Hanna Hong
MFMichael Fritz
Michael Fritz
JKJamie Ku
Jamie Ku
BPBrandon Prendes
Brandon Prendes
EMEric Lamarre MD
Eric Lamarre MD
Background: Resected oral cavity carcinoma defects are often reconstructed with osteocutaneous or soft‐tissue free flaps, but risk of osteoradionecrosis (ORN) is unknown.Methods: This retrospective study included oral cavity carcinoma treated with free‐tissue reconstruction and postoperative IMRT between 2000 and 2019. Risk‐regression assessed risk factors for grade ≥2 ORN.Results: One hundred fifty‐five patients (51% male, 28% current smokers, mean age 62 ± 11 years) were included. Median follow‐up was 32.6 months (range, 1.0–190.6). Thirty‐eight (25%) patients had fibular free flap for mandibular reconstruction, whereas 117 (76%) had soft‐tissue reconstruction. Grade ≥2 ORN occurred in 14 (9.0%) patients, at a median 9.8 months (range, 2.4–61.5) after IMRT. Post‐radiation teeth extraction was significantly associated with ORN. One‐year and 10‐year ORN rates were 5.2% and 10%, respectively.Conclusions: ORN risk was comparable between osteocutaneous and soft‐tissue reconstruction for resected oral cavity carcinoma. Osteocutaneous flaps can be safely performed with no excess concern for mandibular ORN.

1 January 2021 in Oral Oncology
Verified
Journal Article
Closed access
CFChristopher W. Fleming
Christopher W. Fleming
MWMatthew C. Ward
Matthew C. Ward
NWNeil M. Woody
Neil M. Woody
NJNikhil P. Joshi
Nikhil P. Joshi
JGJohn F. Greskovich
John F. Greskovich
SKShlomo A. Koyfman
Shlomo A. Koyfman

30 June 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
ABArslan Babar
Arslan Babar
NWNeil M. Woody
Neil M. Woody
AGAhmed I Ghanem
Ahmed I Ghanem
JTJillian Tsai
Jillian Tsai
NDNeal E. Dunlap
Neal E. Dunlap
JGJessica Geiger
Jessica Geiger
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin. An IRB-approved collaborative database of patients (pts) with primary OCSCC (Stage I–IVB AJCC 7th edition) treated with primary surgical resection between January 2005 and January 2015, with or without adjuvant therapy, was established from six academic institutions. Patients were categorized by cisplatin dose and schedule, and resultant groups compared for demographic data, pathologic features, and outcomes by statistical analysis to determine disease free survival (DFS) and freedom from metastatic disease (DM). From a total sample size of 1282 pts, 196 pts were identified with high-risk features who were treated with adjuvant CRT. Administration schedule of cisplatin was not significantly associated with DFS. On multivariate (MVA), DFS was significantly better in patients without perineural invasion (PNI) and in those receiving ≥200 mg/m2 cisplatin dose (p < 0.001 and 0.007). Median DFS, by cisplatin dose, was 10.5 (<200 mg/m2) vs. 20.8 months (≥200 mg/m2). Our analysis demonstrated cumulative cisplatin dose ≥200 mg/m2 was associated with improved DFS in high-risk resected OCSCC pts.

1 November 2023 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SWShannon S. Wu
Shannon S. Wu
NWNeil Woody
Neil Woody
JHJennifer Hesse
Jennifer Hesse
SCSamantha Cook
Samantha Cook
VCVincent Cracolici
Vincent Cracolici
EMEric Lamarre MD
Eric Lamarre MD
After undergoing surgical resection, patients with oral cavity squamous cell carcinoma (OCSCC) frequently require adjuvant radiation therapy that considers several known risk factors, such as distance to margins and positive surgical margins.1,2 However, the optimal method for accomplishing intraoperative margin assessment, either from the tumor bed (defect-driven sampling) vs from the resected en bloc specimen (specimen-driven sampling), is not well defined.